

Press Release

Excellent results already after only one month

The first international multi-center LASIK study with the SCHWIND AMARIS

Kleinostheim, Germany, September 2007

Excellent visual acuity, extremely high predictability and low variance in results: These were substantiated in one-month results of a recent multi-center LASIK study in which the new excimer laser generation SCHWIND AMARIS was employed for the first time. The study was carried out on 389 eyes by SCHWIND reference surgeons Maria-Clara Arbelaez, MD, Oman, Ioannis Aslanides, MD, Greece, Francesco Carones, MD, Italy, Tobias Neuhann, MD, Germany, as well as Alena Feuermannova, MD and Pavel Rozsival, MD, Czech Republic. Treated patients were myopes, either pure or with astigmatism, between 18 and 60 years of age. The preoperative spherical equivalent (SEQ) ranged from -0.50 D to -8.25 D, and astigmatism was treated up to -5.00 D. All patients were corrected with SCHWIND's „Aberration-Free“ treatment.

Postoperatively, an average SEQ of -0.16 with a very low standard deviation of 0.25 D was observed. In 74 percent of all treated eyes, the planned refractive result was achieved within a minimum deviation of ± 0.25 D already after one month. 93 percent were in the range of ± 0.50 D and 100 percent of eyes within ± 1.00 D (see figure 1). High postoperative stability was already observed after one week. This very rapid convergence toward the planned refractive result implies that the recovery time after surgery with the SCHWIND AMARIS is very short.

Page 2

Again after only one month, more than 92 percent of treated patients attained post-operative uncorrected visual acuity (UCVA) of 20/20 or better. No single patient eye realized a visual acuity of less than 20/32. In 99 percent, an UCVA of 20/25 or better was achieved. More than 32 percent of study participants even achieved visual acuity of 20/16 or better (see figure 2).

Altogether, only very slight scattering of results was observed and no trend toward over- or undercorrections was detected after only one month. All results were obtained without the use of individual nomograms.

„In my opinion, the extraordinary performance of the SCHWIND AMARIS decisively contributed to the excellent clinical results that we have seen so far“, summed up Dr. Maria-Clara Arbelaez, Oman, at the presentation of the multi-center study on the occasion of the ESCRS 2007 in Stockholm.

Contact:

SCHWIND eye-tech-solutions GmbH & Co. KG

Antje Splittdorf

fon: +49 (0) 60 27 / 5 08-164 · fax: +49 (0) 60 27 / 5 08-246

email: antje.splittdorf@eye-tech.net

